Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson & Johnson / Janssen Biotech / Janssen-Cilag / AstraZeneca) and Xtandi (Pfizer / Astellas) are cornerstone treatments for metastatic castrate-resistant prostate cancer (mCRPC). However, the use of second-generation hormonal agents has expanded beyond mCRPC, and they are being positioned in the lucrative nonmetastatic CRPC and metastatic hormone-sensitive settings. The late-phase pipeline for mCRPC has also become more dynamic, with two PARP inhibitors (Johnson & Johnson’s Zejula and Pfizer’s Talzenna), three immune checkpoint inhibitors (Bristol Myers Squibb / Ono Pharmaceutical’s Opdivo, Bristol Myers Squibb / Ono Pharmaceutical’s Yervoy, Merck Sharp and Dohme’s Keytruda), two kinase inhibitors (Array BioPharma / Roche / Genentech / Chugai’s ipatasertib and AstraZeneca’s capivasertib), one radioligand therapy (Novartis’s 177Lu-PSMA-617), and one angiogenesis inhibitor (Exelixis / Takeda / Ipsen’s Cabometyx) in Phase III development.

Questions Answered

  • What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?
  • How is prostate cancer currently managed, and how will treatment practices change in the future?
  • What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning in the market? How will new market entrants fare through 2029?
  • What are the actionable remaining unmet needs affecting the management of prostate cancer? What are the key drug development and therapeutic opportunities?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: More than 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.

Key companies: Johnson & Johnson, Janssen Biotech, Janssen-Cilag, AstraZeneca, Pfizer, Astellas Pharma, Sanofi, Roche, Bayer HealthCare, Clovis Oncology, Merck Sharp & Dohme, Exelixis, Ipsen, Takeda, AstraZeneca, Bristol Myers Squibb, Ono Pharmaceutical, Novartis, Myovant Sciences.

Key drugs: Xtandi (enzalutamide), Zytiga (abiraterone), Erleada (apalutamide), Xofigo (radium-223), Jevtana (cabazitaxel), docetaxel, Yonsa (abiraterone acetate), Nubeqa (darolutamide), Lynparza (olaparib), Rubraca (rucaparib), Talzenna (talazoparib), Zejula (niraparib), Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Cabometyx (cabozantinib), ipatasertib, relugolix, 177Lu-PSMA-617, capivasertib.

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • COVID-19
      • Key Findings
        • Prostate Cancer Key Findings
      • Key Updates
        • January 2021
        • November 2020
        • August 2020
        • April 2020
      • Market Outlook
        • Key Findings
          • Major-Market Share of Prostate Cancer Drug Classes: 2019
          • Major-Market Share of Prostate Cancer Drug Classes: 2029
          • Drug-Treatable Population Share and Major-Market Sales Share: 2019
          • Drug-Treatable Population Share and Major-Market Sales Share: 2029
          • Population Positioning of Therapies in Prostate Cancer
          • Prostate Cancer SWOT Analysis
        • COVID-19: Areas of Potential Forecast Impact
          • Market Drivers and Constraints
            • What Factors Are Driving the Market for Prostate Cancer?
            • What Factors Are Constraining the Market for Prostate Cancer?
            • Major-Market Sales of Key Agents for Prostate Cancer: 2019-2029
            • Major-Market Sales for Prostate Cancer by Region: 2019, 2024, and 2029
            • Major-Market Sales for Prostate Cancer by Drug Class: 2019-2029
          • Segment-Specific Trends
            • Major-Market Share of Hormonal Agents for Hormone-Sensitive Prostate Cancer: 2029
            • Patient-Share Dynamics of Key Agents for Newly Diagnosed, High-Risk and N1M0, Hormone-Sensitive Prostate Cancer in the United States: 2019-2029
            • Patient-Share Dynamics of Key Agents for Biochemically Recurrent, Hormone-Sensitive Prostate Cancer in the United States: 2019-2029
            • Patient-Share Dynamics of Key Agents for Metastatic Hormone-Sensitive Prostate Cancer in the United States: 2019-2029
            • Patient-Share Dynamics of Key Hormonal Agents for Nonmetastatic Castrate-Resistant Prostate Cancer in the United States: 2019-2029
            • Patient-Share Dynamics of Key Therapies in First-Line Metastatic Castrate-Resistant Prostate Cancer in the United States: 2019-2029
            • Patient-Share Dynamics of Key Therapies in First-Line Metastatic Castrate-Resistant Prostate Cancer in France: 2019-2029
            • Share of Major-Market Sales in First-Line Metastatic Castrate-Resistant Prostate Cancer by Agent: 2029
            • Patient-Share Dynamics of Key Therapies in Second-Line Metastatic Castrate-Resistant Prostate Cancer in the United States: 2019-2029
            • Patient-Share Dynamics of Key Therapies in Second-Line Metastatic Castrate-Resistant Prostate Cancer in France: 2019-2029
            • Patient-Share Dynamics of Key Therapies in Third- and Fourth-Line Metastatic Castrate-Resistant Prostate Cancer in the United States: 2019-2029
            • Patient-Share Dynamics of Key Therapies in Third- and Fourth-Line Metastatic Castrate-Resistant Prostate Cancer in France: 2019-2029
            • Share of Major-Market Sales in Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer by Drug Class: 2029
        • Forecast
          • Market Forecast Assumptions
          • Market Forecast Dashboard
        • Etiology and Pathophysiology
          • Key Findings
            • Disease Overview
          • Disease Pathophysiology
            • Biology and Metastatic Spread of Prostate Cancer
            • Prostate-Specific Antigen
            • Key Clinical Uses of Prostate-Specific Antigen as a Biomarker in Prostate Cancer
            • Staging Classification and Grading Systems for Prostate Cancer
            • TNM Staging Classification System for Prostate Cancer
            • Classification of Level of Risk of Recurrence of Prostate Cancer
            • Development of Castrate-Resistant Prostate Cancer
            • Molecular Alterations Involved in Castrate-Resistant Prostate Cancer
          • Key Pathways and Drug Targets
            • Androgen Receptor Signaling Pathway
            • Androgen-Mediated Growth of Normal and Cancerous Prostate Cells
            • Splice Variants of the Androgen Receptor
            • Emerging Drug Targets in Prostate Cancer
            • PARP Inhibition: Mechanism of Action
            • Immune Checkpoint Inhibitors and Modulators
          • Anatomic Location and Architecture of the Prostate Gland
        • Epidemiology
          • Introduction
            • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Newly Diagnosed Incidence of Prostate Cancer
            • Number of Diagnosed Incident Cases of Prostate Cancer in the Major Pharmaceutical Markets: 2019-2029
            • Disease Definition
            • Methods
            • Sources Used for TNM Stage and NCCN Risk Categories of Prostate Cancer
            • Diagnosed Incident Cases of Prostate Cancer in the Major Pharmaceutical Markets by TNM Stage and NCCN Risk Category: 2019-2029
            • Definition
            • Methods
            • Sources Used for Recurrent Incidence of Prostate Cancer
            • Number of Biochemically and Metastatic Recurrent Incident Cases of Prostate Cancer in the Major Pharmaceutical Markets: 2019-2029
            • Sources Used for Prostate Cancer Drug-Treatable Population
            • Number of Drug-Treatable Cases of Prostate Cancer in the Major Pharmaceutical Markets: 2019-2029
            • Prostate Cancer Patient Flow Model
            • Sources Used for Prostate Cancer Drug-Treated Population
            • Number of Drug-Treated Cases of Prostate Cancer in the Major Pharmaceutical Markets: 2019-2029
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Prostate Cancer
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for Prostate Cancer
              • Current Treatments Used for Prostate Cancer
              • Market Events Impacting the Use of Key Current Therapies for Prostate Cancer
              • Advantages and Disadvantages of Zytiga
              • Key Results from Clinical Trials Investigating Zytiga for the Treatment of Prostate Cancer
              • Ongoing Clinical Development of Zytiga
              • Key Ongoing Clinical Trials of Zytiga in the Treatment of Prostate Cancer
              • Expert Insight: Zytiga
              • Advantages and Disadvantages of Xtandi
              • Key Results from Clinical Trials Investigating Xtandi for the Treatment of Prostate Cancer
              • Ongoing Clinical Development of Xtandi
              • Key Ongoing Clinical Trials of Xtandi in the Treatment of Prostate Cancer
              • Expert Insight: Xtandi
              • Key Results from Select Clinical Trials Investigating Erleada for the Treatment of Prostate Cancer
              • Ongoing Clinical Development of Erleada
              • Key Ongoing Clinical Trials of Erleada in the Treatment of Prostate Cancer
              • Expert Insight: Erleada
              • Key Results from Select Clinical Trials Investigating Nubeqa for the Treatment of Prostate Cancer
              • Ongoing Clinical Development of Nubeqa
              • Key Ongoing Clinical Trials of Nubeqa in the Treatment of Prostate Cancer
              • Expert Insight: Nubeqa
              • Key Results from Select Clinical Trials Investigating Yonsa for the Treatment of Prostate Cancer
              • Ongoing Clinical Development of Yonsa
              • Expert Insight: Yonsa
              • Advantages and Disadvantages of LHRH Agonists / Antagonists
              • Expert Insight: LHRH Agonists / Antagonists
              • Advantages and Disadvantages of Provenge
              • Key Results from Clinical Trials Investigating Provenge for the Treatment of Prostate Cancer
              • Ongoing Clinical Development of Provenge
              • Key Ongoing Clinical Trials Investigating Provenge in the Treatment of Prostate Cancer
              • Expert Insight: Provenge
              • Advantages and Disadvantages of Xofigo
              • Key Results from Clinical Trials Investigating Xofigo for the Treatment of Prostate Cancer
              • Ongoing Clinical Development of Xofigo
              • Key Ongoing Clinical Trials of Xofigo in the Treatment of Prostate Cancer
              • Expert Insight: Xofigo
              • Advantages and Disadvantages of Jevtana
              • Key Results from Clinical Trials Investigating Jevtana for the Treatment of Prostate Cancer
              • Ongoing Clinical Development of Jevtana
              • Expert Insight: Jevtana
              • Advantages and Disadvantages of Docetaxel
              • Key Results from Clinical Trials Investigating Docetaxel for the Treatment of Prostate Cancer
              • Expert Insight: Docetaxel
              • Key Results from Select Clinical Trials Investigating Lynparza for the Treatment of Prostate Cancer
              • Ongoing Clinical Development of Lynparza
              • Key Ongoing Clinical Trials of Lynparza in the Treatment of Prostate Cancer
              • Expert Insight: Lynparza
              • Key Results from Clinical Trials Investigating Rubraca for the Treatment of Prostate Cancer
              • Ongoing Clinical Development of Rubraca
              • Key Ongoing Clinical Trials of Rubraca in the Treatment of Prostate Cancer
              • Expert Insight: Rubraca
            • Medical Practice
              • Newly Diagnosed, Low- and Intermediate-Risk Hormone-Sensitive Prostate Cancer
              • Newly Diagnosed, High-Risk and N1M0 Hormone-Sensitive Prostate Cancer
              • Metastatic Hormone-Sensitive Prostate Cancer
              • Biochemically Recurrent Prostate Cancer
              • Nonmetastatic Castrate-Resistant Prostate Cancer
              • First-Line Metastatic Castrate-Resistant Prostate Cancer
              • Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer
              • Prostate Cancer Treatment Guidelines by Market
              • Patient Characteristics Influencing Drug Selection in Prostate Cancer
              • Treatment Decision Tree for Low- and Intermediate-Risk Prostate Cancer: Major Markets
              • Treatment Decision Tree for High-Risk and N1M0 Prostate Cancer: Major Markets
              • Treatment Decision Tree for Nonmetastatic Castrate-Resistant Prostate Cancer: United States
              • Treatment Decision Tree for Metastatic Hormone-Sensitive Prostate Cancer: United States
              • Treatment Decision Tree for Metastatic Castrate-Resistant Prostate Cancer: Major Markets
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in Prostate Cancer
            • Top Unmet Needs in Prostate Cancer: Current and Future Attainment
          • Emerging Therapies
            • Key Findings
              • Pipeline Trends for Prostate Cancer
            • Key Emerging Therapies
              • Key Emerging Therapies in Development for Prostate Cancer
              • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Prostate Cancer
              • Key Results from Select Clinical Trials Investigating ProstAtak for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for ProstAtak
              • Key Ongoing Clinical Trials of ProstAtak in the Treatment of Prostate Cancer
              • Expert Insight: ProstAtak
              • Expectations for Market Authorization and Sales Opportunity of ProstAtak in Prostate Cancer
              • Key Results from Select Clinical Trials Investigating Stapuldencel-T for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for Stapuldencel-T
              • Expert Insight: Stapuldencel-T
              • Expectations for Market Authorization and Sales Opportunity of Stapuldencel-T in Prostate Cancer
              • Key Results from Clinical Trials Investigating Keytruda for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for Keytruda
              • Key Ongoing Clinical Trials of Keytruda in the Treatment of Prostate Cancer
              • Expert Insight: Keytruda
              • Expectations for Market Authorization and Sales Opportunity of Keytruda in Prostate Cancer
              • Key Results from Clinical Trials Investigating Opdivo for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for Opdivo
              • Key Ongoing Clinical Trials of Opdivo in the Treatment of Prostate Cancer
              • Expert Insight: Opdivo
              • Expectations for Market Authorization and Sales Opportunity of Opdivo in Prostate Cancer
              • Key Results from Clinical Trials Investigating Opdivo and Yervoy for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for Opdivo and Yervoy
              • Key Ongoing Clinical Trials of Opdivo and Yervoy in the Treatment of Prostate Cancer
              • Expert Insight: Opdivo and Yervoy
              • Expectations for Market Authorization and Sales Opportunity of Opdivo and Yervoy in Prostate Cancer
              • Key Results from Clinical Trials Investigating Talzenna for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for Talzenna
              • Key Ongoing Clinical Trials of Talzenna in the Treatment of Prostate Cancer
              • Expert Insight: Talzenna
              • Expectations for Market Authorization and Sales Opportunity of Talzenna in Prostate Cancer
              • Key Results from Clinical Trials Investigating Zejula for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for Zejula
              • Key Ongoing Clinical Trials of Zejula in the Treatment of Prostate Cancer
              • Expert Insight: Zejula
              • Expectations for Launch and Sales Opportunity of Zejula in Prostate Cancer
              • Key Results from Select Clinical Trials Investigating Masitinib for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for Masitinib
              • Key Ongoing Clinical Trials of Masitinib in the Treatment of Prostate Cancer
              • Expert Insight: Masitinib
              • Expectations for Market Authorization and Sales Opportunity of Masitinib in Prostate Cancer
              • Key Results from Select Clinical Trials Investigating Ipatasertib for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for Ipatasertib
              • Expert Insight: Ipatasertib
              • Expectations for Market Authorization and Sales Opportunity of Ipatasertib in Prostate Cancer
              • Key Results from Select Clinical Trials Investigating Capivasertib for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for Capivasertib
              • Key Ongoing Clinical Trials of Capivasertib in the Treatment of Prostate Cancer
              • Expert Insight: Capivasertib
              • Expectation for Market Authorization and Sales Opportunity of Capivasertib in Prostate Cancer
              • Key Results from Select Clinical Trials Investigating 177Lu-PSMA-617 for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for 177Lu-PSMA-617
              • Key Ongoing Clinical Trials Investigating 177Lu-PSMA-617 in the Treatment of Prostate Cancer
              • Expert Insight: 177-Lu-PSMA-617
              • Expectations for Market Authorization and Sales Opportunity of 177Lu-PSMA-617 in Prostate Cancer
              • Key Results from Select Clinical Trials Investigating Cabometyx for the Treatment of Prostate Cancer
              • Analysis of Clinical Development Program for Cabometyx
              • Key Ongoing Clinical Trials of Cabometyx in the Treatment of Prostate Cancer
              • Expert Insight: Cabometyx
              • Expectations for Market Authorization and Sales Opportunity of Cabometyx in Prostate Cancer
            • Early-Phase Pipeline Analysis
              • Select Compounds in Early-Phase Development for Prostate Cancer
          • Access and Reimbursement Overview
            • Region-Specific Reimbursement Practices
              • Key Market Access Considerations in Prostate Cancer: United States
              • General Reimbursement Environment: United States
              • Key Market Access Considerations in Prostate Cancer: EU5
              • General Reimbursement Environment: EU5
              • Key Market Access Considerations in Prostate Cancer: Japan
              • General Reimbursement Environment: Japan
          • Appendix
            • Key Abbreviations Related to Prostate Cancer
            • Brands, Marketers, and Generic Availability of Current Therapies Used for Prostate Cancer by Market
            • Prostate Cancer Bibliography

        Author(s): Laura Vinuesa, D.V.M., M.Sc.; Narendra Parihar

        Laura Vinuesa, D.V.M., M.Sc., is a senior business insights analyst on the Oncology team at DRG, part of Clarivate. She specializes in bladder cancer and head and neck cancers and in optimizing market access opportunities for new biomarker-targeted therapies in oncology. Previously at DRG, she was part of the Global Market Access Insights team, for whom she analyzed the healthcare systems and pharmaceutical markets of the EU5 and focused on evolving HTA demands, P&R processes, and stringent cost-containment strategies. She obtained her doctorate in veterinary medicine from Complutense University in Madrid and a master's degree in clinical research and pharmaceutical medicine from EPHOS, School of PharmaStudies, in Madrid.

        Narendra Parihar, M.P.H., is a senior epidemiologist at DRG, part of Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.


        Related Reports

        Prostate Cancer - Geographic Focus: China - Prostate Cancer - China In-Depth (China)

        Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence...

        View Details

        Prostate Cancer - Epidemiology - Mature Markets Data

        DRG Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We repor...

        View Details

        Prostate Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Hormone Sensititve

        The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years with the approval...

        View Details